JO
BCTX

John Overdeck’s Briacell Therapeutics BCTX Stock Holding History

John Overdeck’s Portfolio BCTX Stock Details BCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-129
Closed -$11K – 3204
2024
Q4 		$11K Buy
+129
New +$15.5K ﹤0.01% 3132
2021
Q4 		– Sell
-414
Closed -$503K – 4281
2021
Q3 		$503K Buy
+414
New +$381K ﹤0.01% 3258

Other funds holding BCTX

UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $140B AUM 46.34% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
CWP
Concord Wealth Partners Abingdon, Virginia $873M AUM 24.02% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
HWA
HHM Wealth Advisors Chattanooga, Tennessee $996M AUM 23.11% 1-Year Est. Return

John Overdeck's BCTX Position: Q1 2025 in Review

John Overdeck sold out of Briacell Therapeutics (BCTX) in Q1 2025, closing a stake of 129 shares — an estimated $11K sold.

John Overdeck first reported a position in BCTX in Q3 2021 and held it in 2 quarters. The position peaked at $503K in Q3 2021. 13 funds tracked by Wall St. Rank hold BCTX as of Q1 2025.

  • John Overdeck reported no remaining Briacell Therapeutics position as of Q1 2025 after selling out during the quarter.
  • John Overdeck sold 129 Briacell Therapeutics shares in Q1 2025, an estimated $11K.
  • John Overdeck first reported a position in Briacell Therapeutics in Q3 2021 and held it in 2 quarters.
  • John Overdeck's Briacell Therapeutics position peaked at $503K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.